Wednesday October 18th 2017

Active Biotech, Teva remain committed to NERVENTRA clinical development program for multiple sclerosis

Teva Pharmaceutical Industries Ltd. and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that both companies remain committed to the NERVENTRA® (laquinimod) clinical development program for multiple sclerosis (MS) following the announcement of a negative opinion for the treatment of relapsing-remitting multiple sclerosis (RRMS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

Source article:  

Active Biotech, Teva remain committed to NERVENTRA clinical development program for multiple sclerosis

Leave a Comment

More from category

Discovery may lead to new approach for treating MS
Discovery may lead to new approach for treating MS

Around 2.5 million people are affected by the autoimmune disease Multiple Sclerosis (MS), the commonest central nervous [Read More]

Roche to present new OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive forms of multiple sclerosis at ECTRIMS
Roche to present new OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive forms of multiple sclerosis at ECTRIMS

Roche announced today that new data on OCREVUS ® (ocrelizumab) in people with relapsing and primary progressive forms [Read More]

All you need to know about dysesthesia
All you need to know about dysesthesia

Dysesthesia is a painful, itchy sensation, often associated with multiple sclerosis (MS). Learn more about the symptoms [Read More]

Medical News Today: All you need to know about dysesthesia
Medical News Today: All you need to know about dysesthesia

Dysesthesia is a painful, itchy sensation, often associated with multiple sclerosis (MS). Learn more about the symptoms [Read More]

MRI brain scans can reveal MS risk in children before clinical symptoms appear
MRI brain scans can reveal MS risk in children before clinical symptoms appear

By the time multiple sclerosis (MS) is diagnosed in children, it may be difficult to prevent the disabilities and [Read More]